FTSE 100 news / Companies and sectors / Pharma and healthcare / 15 October 2026
Pharma and healthcare: sector news on Thursday 15 October 2026
Average tone +3.3 (positive) across 5 companies with relevant coverage, from 74 stories.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| GSK | +1.3 | 34 | Coverage was split between GSK's $800 million Pennsylvania manufacturing investment, along with supportive analyst views and a share price rise, and reports of up to 1,217 job cuts in Belgium under its restructuring. |
| AstraZeneca | +7.5 | 30 | Coverage centred on a sharp share price rise, with upgrades, higher price targets and oncology deals cited. |
| Convatec | +4.5 | 4 | Coverage was mainly about a non-executive director buying shares, which reads as a vote of confidence. |
| Haleon | +5.5 | 3 | Coverage was mildly positive, with commentary on Sensodyne helping the latest results and a valuation piece calling the shares undervalued on cash flow. |
| Smith & Nephew | −2.3 | 3 | Coverage centred on Smith & Nephew cutting its sales outlook, which put the stock under scrutiny. |
Strongest stories in the sector
- +10.0 AstraZeneca Stock Price Forecast — AZN ($161.59) Rallies 3.7% Off 52-Week Low on Defensive Bid and Double Upgrade — $169 Target
Rally off low with double upgrade and higher target - +9.3 AstraZeneca PLC Stock Draws Upgrades As Oncology Deals Accelerate
Upgrades as oncology deals accelerate - +9.2 FTSE 100 Climbs to 10,724.86, a Three-Week High, as AstraZeneca, GSK and Defence Stocks Lead
Shares led FTSE 100 to three-week high - +9.2 AstraZeneca PLC (AZN) Shares Surge 4.0% -- What GF Score of 76 T
Shares surged 4.0% - +9.2 AstraZeneca PLC Draws Bullish Targets As Oncology Deals Mount
Bullish targets as oncology deals mount - +9.2 GSK to invest $800M in Pennsylvania, adding 300 jobs
$800M US investment and 300 jobs signals growth commitment - +9.2 Governor Shapiro Secures Over $800 Million Investment from GSK to Expand Operations, Creating Over 300 New Jobs and Growing Pennsylvania’s Robust Life Sciences Industry
Major $800M Pennsylvania investment announced - −9.2 Why Is Smith & Nephew (LSE:SN.) Stock Under Scrutiny After Cutting Its Sales Outlook?
Cut to sales outlook puts stock under scrutiny. - +8.8 AstraZeneca Stock Draws Bullish Targets As Oncology Deals Pile Up
Bullish targets on oncology deals - +8.7 AstraZeneca PLC Stock Gains Favor As Oncology Deals Mount
Stock gains favour on oncology deals - +8.3 AstraZeneca PLC Stock (AZN) Moved Up by 3.81% on Oct 14: A Full Analysis
Shares moved up 3.81% - +8.3 Why AstraZeneca (AZN) Stock Is Up Today
Stock up on the day
Pharma and healthcare: every day · FTSE 100 overview for the day